Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis: Specnuezhenide suppresses diabetes-induced bone loss

Diabetes osteoporosis is a chronic complication of diabetes mellitus (DM) and is associated with osteoclast formation and enhanced bone resorption. Specnuezhenide (SPN) is an active compound with anti-inflammatory and immunomodulatory properties. However, the roles of SPN in diabetic osteoporosis re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xiaoshuang, Jiang, Juanjuan, Yang, Juan, Yan, Wenyan, Jiang, Luyue, Chen, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827798/
https://www.ncbi.nlm.nih.gov/pubmed/35929595
http://dx.doi.org/10.3724/abbs.2022094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827798/
https://www.ncbi.nlm.nih.gov/pubmed/35929595
http://dx.doi.org/10.3724/abbs.2022094

Ejemplares similares